Nature de la demande
Radiation
Arrêt du remboursement suite à un arrêt de commercialisation.
Avis favorable à l’arrêt du remboursement de la spécialité IMBRUVICA (ibrutinib) 140 mg, gélule dans les indications de l’AMM.
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
hb7FgRNfA0D52TvM
